ESGBERT/base_data · Datasets at Hugging Face

sentence stringlengths 1 23.5k ⌀
Ana was among the were honored at the Regeneron Science Talent Search awards gala.
A total of $including $2,000 to each of the top 300 scholars and their schools.
In alumni in internship positions across our company, providing a pathway for them to enter STEM careers.
“WE ARE ALWAYS INSPIRED BY THE WORK OF THESE TALENTED YOUNG PEOPLE, AND THIS YEAR’S WINNERS HAVE IMPRESSED US WITH THEIR CURIOSITY AND DESIRE TO IMPROVE THE WORLD AROUND THEM.
Responsibility Report We think it’s important to give back to our communities to build their resiliency and ensure our neighbors are equipped to respond and adapt to changes and challenges.
We draw on our skills, resources and highly engaged employees to make a difference in the lives of many.
on the Civic which recognizes the most community-minded companies in the U.S.
In donated more than 27,800 hours to local non-profit organizations through our volunteer programs.
This is in the top-quartile of corporate volunteer participation rates, and well above the according to the Chief Executives for Corporate Purpose 2019 benchmarking study.
They also contributed close to $1,188 non-profit organizations.
We use leading strategies to actively engage employees in our community efforts.
We enlist the support and championship of employee ambassadors to help drive recruitment and promote volunteer activities year-round and on our annual day of service, Day for Doing Good.
We also mobilize our leaders to encourage their departments to volunteer to foster camaraderie and help with team building.
For Good, our employee-giving program, is built on our long-term commitment to support our colleagues’ passion for their causes and local communities.
As we grow, we are intent on keeping our employees engaged by building a consistent volunteer and giving experience that prioritizes choice and convenience with numerous options for volunteering with and donating to the nonprofits they care about most.
For Doing Good (DD4DG celebrated its third year in October, mobilizing thousands of employees on a global scale to create positive change in the communities where they live and work.
In collectively volunteering more than 16,000 hours at 155 organizations in 70 communities around the world.
Their efforts had an impact across a wide variety of areas — providing a warm meal and conversation for military veterans, packing meals for those in need, creating a comfortable environment for shelter animals, sparking young students’ love for science and helping to beautify and preserve local parks.
“WE LOOK FORWARD TO WORKING WITH REGENERON ON THEIR ANNUAL DAY FOR DOING GOOD AS WE’VE SEEN FIRSTHAND THE IMPACT THEY’RE MAKING ON THE COMMUNITY.
of non-profit leaders surveyed indicated the program will improve their organization’s effectiveness.
of Regeneron employees surveyed confirmed participation enhanced their leadership competencies.
KEY OUTCOMES Matching Gift Program Our Matching Gift Program offers to match employees’ eligible charitable donations of $U.S.-based public charities, doubling the impact of their contributions.
In $1 million through the Matching Gift Program.
In our international employees, magnifying the impact of employee giving around the world.
Using Data For Good A Regeneron pro bono program in collaboration with the Taproot Foundation, Using Data For Good leverages our employees’ expertise to help diagnose and improve upon pain points that non-profits are experiencing with data collection systems and processes.
The program gives Regeneron participants the opportunity to practice key leadership skills, network with colleagues and work with inspiring non-profit executives.
In of Regeneron subject matter experts worked with nine non-profit partners, up from five in 2018.
For example, one team partnered with Westchester Children’s Association (WCA) to develop a model for sustainable data analysis, mapping data flow from collection to output to analysis.
According to WCA, the project gave them a greater understanding of how the organization’s data can be used to validate and showcase the important work they do in the advocacy world.
VTO provides all eligible full-time employees the opportunity to volunteer with an eligible non-profit organization up to eight hours per calendar year during regularly scheduled work hours.
VTO encourages colleagues to volunteer on their terms — no matter when or how they choose to serve.
Our direct economic contributions include wages for our employees, contractors and suppliers, capital investments and taxes paid to governments.
We are committed to hiring local suppliers whenever possible.
New York State In New York State, we have invested more than $in our office, labs and manufacturing infrastructure over the past four years.
In compensation of more than $845 million² to employees based within New York State.
In the New York Capital Region, Regeneron IOPS is one of the largest employers.
In Fall commitment to spend $800 million through 2025 to expand our facilities and capabilities in the Capital Region and create an additional 1,500 jobs.
At our Red Mill Campus in Rensselaer, our newest addition will be ready for occupancy in 2020, with additional building investments on the site underway.
Construction is ongoing on a at our new Tempel Lane campus, where vials and syringes will be filled for clinical and commercial use and commercial product will be labeled and packaged.
Responsibility Report SNAPSHOT / Ireland 900+ employees live within Ireland¹ $1B+ investment in past five years Ireland Since we first announced plans to build operations in Ireland in 2014, we have made investments of more than $1 billion, transforming a vacant former computer-manufacturing factory in Limerick into a state-of-the-art bulk biologics production facility that is the largest in the country.
In we employed more than 900 people in Ireland.
In the second quarter of in the presentation of its consolidated financial statements relating to certain reimbursements and other payments for products developed and commercialized with collaborators.
As of December 2. 2019 percentages sum to more than 100 percent due to rounding 3.
This covers the OSHA categories of Needlestick Sharps and Abraded/punctured/scratched/laceration 4.
Renewable Energy Usage (%) N/A N/A N/A N/A = Not available 1.
Regeneron continues to expand its disclosure across scope 3 categories.
Water³ Total Water Usage (megaliters)⁵ N/A = Not available 1.
As of December 2. 2019 waste figures exclude construction and demolition waste 3. 2016 and 2017 data covers Regeneron-owned sites.
The SASB index below indicates how Regeneron’s public reporting aligns with the Biotechnology and Pharmaceuticals industry standards.
Unlike the top of seven FDA-approved medicines, of which Regeneron records the U.S. net product sales for four as of April 2020.
Percentage change in: (increase compared to previous year Not reported.
This report includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (where applicable, together with its subsidiaries, “Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements.
Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.
Industries Ltd. (or their respective affiliated companies, as applicable), to be canceled or terminated without any further product success; and risks associated with intellectual property of others and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to Dupixent and Praluent), other litigation and other proceedings and government investigations relating to the Company and/or its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition.
Since our founding in on transforming the lives of people living with rare and devastating diseases through the development and delivery of valued innovative medicines.
While the company has grown and changed in countless ways since then, our commitment to serving patients has remained steadfast throughout our history.
Today, we continue to keep patients at the center of all we do – they are our Guiding Star – as we also embrace corporate social responsibility (CSR) in a manner that embodies our mission, while providing value for all of our stakeholders.
Information about our response to this critical issue can be found on our website.
Alexion's mission-driven approach inspires us, giving us even more reason to believe in the importance of our purpose and perform at our personal best.
and our commitment to being a responsible corporate citizen helps make it possible.
is a journey of continuous improvement and that we’ll always have more to do.
for this work, Alexion’s CSR-STAR Platform (see Page of our approach: Serve Communities and Sustain Our Planet, Transform Patient Lives, Advance Our People and Our Company, and Redefine What it Means to Live with a Rare Disease.
a substantive research exercise to identify and prioritize the CSR-related topics most important to our many stakeholders and the success of the company.
We engaged dozens of perspectives in that process, including those from patient organizations, employees, investors, former regulators, community groups, environmental NGOs, recruitment firms and research organizations.
We also looked to widely accepted CSR and pharma industry frameworks for guidance and inspiration.
Launching the International Compliance Champions program to reinforce our foundation of ethics and compliance.
Our approximately critical in getting us to this point, but in many ways, we have just begun.
by this progress and look forward to seeing how this manifests in our CSR commitment and ushers in brighter futures for all of our stakeholders.
Our culture is rooted in integrity, inclusiveness, and our dedication to joining and supporting the communities in which we live and work.
, Alexion has worked to transform the lives of people living with rare and devastating diseases through the development and delivery of innovative medicines, supportive technologies and healthcare services.
their journeys, which fuels all of our efforts, beginning with our own medicine discovery efforts, as well as collaboration with external partners.
We continue to deepen our understanding of rare diseases, having pioneered the field of complement biology.
evolve into new areas, where there is great unmet need and opportunity to help patients and families fully live their best lives.
CSR-STAR (see Page while creating value for all of our stakeholders.
All of this is made possible by the passion of our people, which drives us to continuously innovate and create meaningful value in all we do.
ours, people living with rare diseases and the communities we serve.
Located in the heart of one of the world’s largest biopharmaceutical innovation hubs, Alexion is a global leader in developing and delivering therapies for the treatment of complement-mediated diseases.
hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).
COMPLEMENT BIOLOGY Alexion is a pioneer in the complex field of complement biology, a branch of the immune system that is a part of our body’s natural defense against bacteria.
When inappropriately triggered, the complement system attacks healthy cells, causing significant harm to the body.
of red blood cells) that is mediated by an uncontrolled activation of the complement system, a part of the immune system.
• Atypical Hemolytic Uremic Syndrome (aHUS) – aHUS is a severe and lifethreatening, ultra-rare genetic disease characterized by chronic uncontrolled complement activation and thrombotic microangiopathy (TMA), the formation of blood clots in small blood vessels throughout the body, causing a reduction in platelet count (thrombocytopenia) and life-threatening damage to the kidney, brain, heart and other vital organs.
multiple systems of the body, leading to debilitating or life-threatening complications.
by defective bone mineralization that can lead to deformity of bones and other skeletal abnormalities, as well as systemic complications such as profound muscle weakness, seizures, pain and respiratory failure leading to premature death in infants.
Lysosomal Acid Lipase Deficiency (LAL Deficiency or LAL-D) – LAL-D is a serious, life-threatening ultra-rare disease associated with premature mortality and significant morbidity.
• Neuromyelitis Optica Spectrum Disorder (NMOSD) – Relapsing NMOSD is a severe and ultra-rare autoimmune disease of the central nervous system that primarily affects the optic nerves and the spinal cord.
Each relapse of the disorder results in a stepwise accumulation of disability, including blindness and paralysis, and sometimes premature death.
Complement activation due to anti-AQPone of the primary underlying causes of the destruction of vital cells in the central nervous system in patients with NMOSD.
impaired movement, gait, speech, swallowing and psychiatric disorders.
Anemia (WAIHA) – WAIHA is a rare autoimmune disorder caused by pathogenic Immunoglobulin G (IgG) antibodies that react with and cause the premature destruction of red blood cells at normal body temperature.
severe and life-threatening hemolysis, severe weakness, enlarged spleen and/or liver, rapid heart rate (tachycardia), chest pain, heart failure and fainting (syncope).
We’re building on our fundamental understanding of complement biology and advancing our core therapeutic areas of hematology, nephrology, neurology, metabolics and cardiology.
ETHICS & COMPLIANCE: OUR FOUNDATION We build trust when we make the right choices and act with integrity.
We invest in our communities and shared planet in support of those who depend on us today and for generations that follow.
We urgently seek to understand patient journeys, find answers, and collaborate to deliver access to therapies that change lives.
We pioneered complement biology, spurring new treatments for devastating disorders.
We work to advance healthcare through innovative diagnostics and proactive transparency.
OUR COMPANY We aspire to become the most rewarding company to work for, embracing belonging, and governing and managing our business to return value to our stakeholders.
At Alexion, we take a comprehensive view of CSR, which encompasses environmental, social and governance topics that impact our business and our stakeholders.
We have undertaken significant groundwork to identify and prioritize our most important CSR-related topics (see CSR Materiality Assessment, Page 14).

Ana was among the were honored at the Regeneron Science Talent Search awards gala.

A total of $including $2,000 to each of the top 300 scholars and their schools.

In alumni in internship positions across our company, providing a pathway for them to enter STEM careers.

“WE ARE ALWAYS INSPIRED BY THE WORK OF THESE TALENTED YOUNG PEOPLE, AND THIS YEAR’S WINNERS HAVE IMPRESSED US WITH THEIR CURIOSITY AND DESIRE TO IMPROVE THE WORLD AROUND THEM.

Responsibility Report We think it’s important to give back to our communities to build their resiliency and ensure our neighbors are equipped to respond and adapt to changes and challenges.

We draw on our skills, resources and highly engaged employees to make a difference in the lives of many.

on the Civic which recognizes the most community-minded companies in the U.S.

In donated more than 27,800 hours to local non-profit organizations through our volunteer programs.

This is in the top-quartile of corporate volunteer participation rates, and well above the according to the Chief Executives for Corporate Purpose 2019 benchmarking study.

They also contributed close to $1,188 non-profit organizations.

We use leading strategies to actively engage employees in our community efforts.

We enlist the support and championship of employee ambassadors to help drive recruitment and promote volunteer activities year-round and on our annual day of service, Day for Doing Good.

We also mobilize our leaders to encourage their departments to volunteer to foster camaraderie and help with team building.

For Good, our employee-giving program, is built on our long-term commitment to support our colleagues’ passion for their causes and local communities.

As we grow, we are intent on keeping our employees engaged by building a consistent volunteer and giving experience that prioritizes choice and convenience with numerous options for volunteering with and donating to the nonprofits they care about most.

For Doing Good (DD4DG celebrated its third year in October, mobilizing thousands of employees on a global scale to create positive change in the communities where they live and work.

In collectively volunteering more than 16,000 hours at 155 organizations in 70 communities around the world.

Their efforts had an impact across a wide variety of areas — providing a warm meal and conversation for military veterans, packing meals for those in need, creating a comfortable environment for shelter animals, sparking young students’ love for science and helping to beautify and preserve local parks.

“WE LOOK FORWARD TO WORKING WITH REGENERON ON THEIR ANNUAL DAY FOR DOING GOOD AS WE’VE SEEN FIRSTHAND THE IMPACT THEY’RE MAKING ON THE COMMUNITY.

of non-profit leaders surveyed indicated the program will improve their organization’s effectiveness.

of Regeneron employees surveyed confirmed participation enhanced their leadership competencies.

KEY OUTCOMES Matching Gift Program Our Matching Gift Program offers to match employees’ eligible charitable donations of $U.S.-based public charities, doubling the impact of their contributions.

In $1 million through the Matching Gift Program.

In our international employees, magnifying the impact of employee giving around the world.

Using Data For Good A Regeneron pro bono program in collaboration with the Taproot Foundation, Using Data For Good leverages our employees’ expertise to help diagnose and improve upon pain points that non-profits are experiencing with data collection systems and processes.

The program gives Regeneron participants the opportunity to practice key leadership skills, network with colleagues and work with inspiring non-profit executives.

In of Regeneron subject matter experts worked with nine non-profit partners, up from five in 2018.

For example, one team partnered with Westchester Children’s Association (WCA) to develop a model for sustainable data analysis, mapping data flow from collection to output to analysis.

According to WCA, the project gave them a greater understanding of how the organization’s data can be used to validate and showcase the important work they do in the advocacy world.

VTO provides all eligible full-time employees the opportunity to volunteer with an eligible non-profit organization up to eight hours per calendar year during regularly scheduled work hours.

VTO encourages colleagues to volunteer on their terms — no matter when or how they choose to serve.

Our direct economic contributions include wages for our employees, contractors and suppliers, capital investments and taxes paid to governments.

We are committed to hiring local suppliers whenever possible.

New York State In New York State, we have invested more than $in our office, labs and manufacturing infrastructure over the past four years.

In compensation of more than $845 million² to employees based within New York State.

In the New York Capital Region, Regeneron IOPS is one of the largest employers.

In Fall commitment to spend $800 million through 2025 to expand our facilities and capabilities in the Capital Region and create an additional 1,500 jobs.

At our Red Mill Campus in Rensselaer, our newest addition will be ready for occupancy in 2020, with additional building investments on the site underway.

Construction is ongoing on a at our new Tempel Lane campus, where vials and syringes will be filled for clinical and commercial use and commercial product will be labeled and packaged.

Responsibility Report SNAPSHOT / Ireland 900+ employees live within Ireland¹ $1B+ investment in past five years Ireland Since we first announced plans to build operations in Ireland in 2014, we have made investments of more than $1 billion, transforming a vacant former computer-manufacturing factory in Limerick into a state-of-the-art bulk biologics production facility that is the largest in the country.

In we employed more than 900 people in Ireland.

In the second quarter of in the presentation of its consolidated financial statements relating to certain reimbursements and other payments for products developed and commercialized with collaborators.

As of December 2. 2019 percentages sum to more than 100 percent due to rounding 3.

This covers the OSHA categories of Needlestick Sharps and Abraded/punctured/scratched/laceration 4.

Renewable Energy Usage (%) N/A N/A N/A N/A = Not available 1.

Regeneron continues to expand its disclosure across scope 3 categories.

Water³ Total Water Usage (megaliters)⁵ N/A = Not available 1.

As of December 2. 2019 waste figures exclude construction and demolition waste 3. 2016 and 2017 data covers Regeneron-owned sites.

The SASB index below indicates how Regeneron’s public reporting aligns with the Biotechnology and Pharmaceuticals industry standards.

Unlike the top of seven FDA-approved medicines, of which Regeneron records the U.S. net product sales for four as of April 2020.

Percentage change in: (increase compared to previous year Not reported.

This report includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron Pharmaceuticals, Inc. (where applicable, together with its subsidiaries, “Regeneron” or the “Company”), and actual events or results may differ materially from these forward-looking statements.

Words such as “anticipate,” “expect,” “intend,” “plan,” “believe,” “seek,” “estimate,” variations of such words, and similar expressions are intended to identify such forward-looking statements, although not all forward-looking statements contain these identifying words.

Industries Ltd. (or their respective affiliated companies, as applicable), to be canceled or terminated without any further product success; and risks associated with intellectual property of others and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to Dupixent and Praluent), other litigation and other proceedings and government investigations relating to the Company and/or its operations, the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron’s business, prospects, operating results, and financial condition.

Since our founding in on transforming the lives of people living with rare and devastating diseases through the development and delivery of valued innovative medicines.

While the company has grown and changed in countless ways since then, our commitment to serving patients has remained steadfast throughout our history.

Today, we continue to keep patients at the center of all we do – they are our Guiding Star – as we also embrace corporate social responsibility (CSR) in a manner that embodies our mission, while providing value for all of our stakeholders.

Information about our response to this critical issue can be found on our website.

Alexion's mission-driven approach inspires us, giving us even more reason to believe in the importance of our purpose and perform at our personal best.

and our commitment to being a responsible corporate citizen helps make it possible.

is a journey of continuous improvement and that we’ll always have more to do.

for this work, Alexion’s CSR-STAR Platform (see Page of our approach: Serve Communities and Sustain Our Planet, Transform Patient Lives, Advance Our People and Our Company, and Redefine What it Means to Live with a Rare Disease.

a substantive research exercise to identify and prioritize the CSR-related topics most important to our many stakeholders and the success of the company.

We engaged dozens of perspectives in that process, including those from patient organizations, employees, investors, former regulators, community groups, environmental NGOs, recruitment firms and research organizations.

We also looked to widely accepted CSR and pharma industry frameworks for guidance and inspiration.

Launching the International Compliance Champions program to reinforce our foundation of ethics and compliance.

Our approximately critical in getting us to this point, but in many ways, we have just begun.

by this progress and look forward to seeing how this manifests in our CSR commitment and ushers in brighter futures for all of our stakeholders.

Our culture is rooted in integrity, inclusiveness, and our dedication to joining and supporting the communities in which we live and work.

, Alexion has worked to transform the lives of people living with rare and devastating diseases through the development and delivery of innovative medicines, supportive technologies and healthcare services.

their journeys, which fuels all of our efforts, beginning with our own medicine discovery efforts, as well as collaboration with external partners.

We continue to deepen our understanding of rare diseases, having pioneered the field of complement biology.

evolve into new areas, where there is great unmet need and opportunity to help patients and families fully live their best lives.

CSR-STAR (see Page while creating value for all of our stakeholders.

All of this is made possible by the passion of our people, which drives us to continuously innovate and create meaningful value in all we do.

ours, people living with rare diseases and the communities we serve.

Located in the heart of one of the world’s largest biopharmaceutical innovation hubs, Alexion is a global leader in developing and delivering therapies for the treatment of complement-mediated diseases.

hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D).

COMPLEMENT BIOLOGY Alexion is a pioneer in the complex field of complement biology, a branch of the immune system that is a part of our body’s natural defense against bacteria.

When inappropriately triggered, the complement system attacks healthy cells, causing significant harm to the body.

of red blood cells) that is mediated by an uncontrolled activation of the complement system, a part of the immune system.

• Atypical Hemolytic Uremic Syndrome (aHUS) – aHUS is a severe and lifethreatening, ultra-rare genetic disease characterized by chronic uncontrolled complement activation and thrombotic microangiopathy (TMA), the formation of blood clots in small blood vessels throughout the body, causing a reduction in platelet count (thrombocytopenia) and life-threatening damage to the kidney, brain, heart and other vital organs.

multiple systems of the body, leading to debilitating or life-threatening complications.

by defective bone mineralization that can lead to deformity of bones and other skeletal abnormalities, as well as systemic complications such as profound muscle weakness, seizures, pain and respiratory failure leading to premature death in infants.

Lysosomal Acid Lipase Deficiency (LAL Deficiency or LAL-D) – LAL-D is a serious, life-threatening ultra-rare disease associated with premature mortality and significant morbidity.

• Neuromyelitis Optica Spectrum Disorder (NMOSD) – Relapsing NMOSD is a severe and ultra-rare autoimmune disease of the central nervous system that primarily affects the optic nerves and the spinal cord.

Each relapse of the disorder results in a stepwise accumulation of disability, including blindness and paralysis, and sometimes premature death.

Complement activation due to anti-AQPone of the primary underlying causes of the destruction of vital cells in the central nervous system in patients with NMOSD.

impaired movement, gait, speech, swallowing and psychiatric disorders.

Anemia (WAIHA) – WAIHA is a rare autoimmune disorder caused by pathogenic Immunoglobulin G (IgG) antibodies that react with and cause the premature destruction of red blood cells at normal body temperature.

severe and life-threatening hemolysis, severe weakness, enlarged spleen and/or liver, rapid heart rate (tachycardia), chest pain, heart failure and fainting (syncope).

We’re building on our fundamental understanding of complement biology and advancing our core therapeutic areas of hematology, nephrology, neurology, metabolics and cardiology.

ETHICS & COMPLIANCE: OUR FOUNDATION We build trust when we make the right choices and act with integrity.

We invest in our communities and shared planet in support of those who depend on us today and for generations that follow.

We urgently seek to understand patient journeys, find answers, and collaborate to deliver access to therapies that change lives.

We pioneered complement biology, spurring new treatments for devastating disorders.

We work to advance healthcare through innovative diagnostics and proactive transparency.

OUR COMPANY We aspire to become the most rewarding company to work for, embracing belonging, and governing and managing our business to return value to our stakeholders.

At Alexion, we take a comprehensive view of CSR, which encompasses environmental, social and governance topics that impact our business and our stakeholders.

We have undertaken significant groundwork to identify and prioritize our most important CSR-related topics (see CSR Materiality Assessment, Page 14).